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Abstract
The present study evaluated changes in the incidence of invasive pneumococcal disease (IPD) and the pattern of serotypes isolated in
Navarre, Spain, after the introduction and increased coverage of the heptavalent pneumococcal conjugate vaccine (PCV7). All cases with
isolation of pneumococcus from normally sterile bodily ﬂuids were included. The incidence of IPD in children and adults was compared
for the periods 2001–2002 and 2006–2007. By the end of 2002, only 11% of children aged <5 years had received any dose of PCV7,
whereas, beginning in 2007, the proportion exceeded 50%. Among the cases of IPD aged <5 years, the percentage of those vaccinated
increased from 7% during 2001–2002 to 53% during 2006–2007 (p <0.001). The incidence of IPD from PCV7-serotypes decreased by
85% in children <5 years (p <0.001), by 45% in the population aged 5–64 years (p 0.10) and by 68% in those ‡65 years (p 0.004). By
contrast, the incidence of IPD from non-PCV7 serotypes increased by 40% overall (p 0.006). The incidence of IPD from all serotypes
did not change signiﬁcantly in children <5 years (from 83 to 72 per 100 000) or in the total population (from 15.8 to 16.3 per
100 000). The percentage of cases as a result of serotypes 7 and 19A increased signiﬁcantly in both children and adults. No signiﬁcant
changes were seen in the clinical forms of IPD. The pattern of serotypes causing IPD has changed, in both children and adults, following
the increased coverage of PCV7, although the incidence has been reduced only slightly.
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Introduction
Streptococcus pneumoniae is a frequent cause of serious dis-
ease in the very young and the very old, as well as in those
who are immunosuppressed. Over 90 serotypes of pneumo-
coccus exist, many of which can produce invasive pneumo-
coccal disease (IPD) [1,2]. The heptavalent pneumococcal
conjugate vaccine (PCV7, PrevnarTM, Wyeth Lederle Vac-
cines, Madison, NJ, USA) has been shown to be effective in
preventing IPD caused by vaccine serotypes [3,4]. Subsequent
to its introduction in the USA childhood vaccination schedule,
the overall incidence of IPD in children has been substantially
reduced [5–8]. PCV7 reduces nasopharyngeal carriage of vac-
cine serotypes and can affect pneumococcal transmission in
the community [9]. Indeed, sharp declines in the incidence of
IPD in adults have been seen in the USA subsequent to the
expansion of childhood vaccination [6,10,11].
The effectiveness of PCV7 is determined by the pneumo-
coccal serotypes in circulation in each place, and this could
explain the large differences among regions [12]. However,
few studies have examined the impact of PCV7 in places
where the circulating pneumococcal serotypes did not corre-
spond well with those included in the PCV7 [12–14].
According to the pneumococcal samples processed in
Spain’s reference laboratory between 1990 and 1996, only
68% of the serotypes isolated in IPD cases of all ages were
included in the PCV7 [15], indicating that this vaccine cov-
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ered a smaller proportion of circulating serotypes than in
other developed countries [1].
In Spain, PCV7 was marketed in June 2001. Most regions
have not included it in the childhood vaccination schedule,
except for children with risk factors; it has, however, come
into much wider use because some paediatricians recom-
mend it for all children aged <2 years [16]. We analysed
active IPD surveillance data in Navarre, Spain, to evaluate
the impact of PCV7 on the incidence of the disease in both
children and adults.
Materials and Methods
Active pneumococcal surveillance
Active surveillance of IPD cases in Navarre (600 000 inhabit-
ants) began in 2000, with the participation of all six microbiol-
ogy laboratories in the region. This system has detected 100%
of the hospital discharges in the region with a diagnosis of IPD.
The present analysis includes all cases of IPD diagnosed in Na-
varre between 2001 and 2007. A case of IPD was considered
to be one that was clinically compatible and in which S. pneu-
moniae was isolated in blood, spinal ﬂuid or other normally
sterile body sites. The pneumococcal isolates were sent to the
reference laboratory of the Instituto de Salud Carlos III, where
serotyping was performed by the Quellung reaction or dot-
blot assay [17]. Cases in which PCV7 serotypes (4, 6B, 9V, 14,
18C, 19F and 23F) were isolated were considered separately
in the analyses. Some pneumococci isolated from cases could
not be serotyped because of problems associated with their
conservation or shipment to the reference laboratory. For
rate calculations, case patients missing serotype results were
distributed according to those with known types for the same
period and age group [6,11].
Pneumococcal vaccination
The number of doses of vaccine sold in Navarre has increased
progressively. According to data available in the vaccine regis-
try on doses administered in the public health care system, the
percentage of children <5 years who had received any dose of
PCV7 by the end of the year between 2001 and 2007 was 5%,
11%, 20%, 30%, 42%, 51% and 59%, respectively. The number
of PCV7 doses registered represented 94% of those sold in
the region. Until 2007, the 23-valent anti-pneumococcal vac-
cine was used only in persons with predisposing diseases and
in nursing home residents; not until the end of that year did it
begin to be systematically applied to persons ‡65 years of age.
In IPD cases in children <5 years, we considered the num-
ber of doses of PCV7 received up to 15 days before symptom
onset. In accordance with the schedule recommended by the
manufacturer, we deﬁned complete vaccination as: three doses
of PCV7, if vaccination began between 2 and 6 months of age;
two doses, if it began between 7 and 23 months; and one dose
if vaccination began at 24 months or older. A booster dose
was also required during the second year of life in children
who began vaccination before 12 months of age. Incomplete
vaccination was considered to be the receipt of at least one
dose of PCV7, but without completing the age-appropriate
schedule.
Statistical analysis
The denominators for calculating the rates were the popula-
tion residing in Navarre on 1 January. To provide more stable
results, we compared the mean annual rates in the period
2001–2002, when PCV7 use was limited, and 2006–2007,
when a substantial proportion of children had been vaccinated.
Changes in incidence between periods were assessed as
percentage changes in rates (((rate20062007rate20012002)=
rate20012002) 100) between the two periods. Proportions
were compared using the v2 test or Fisher’s exact test,
and means were compared with Wilcoxon’s test. Exact
methods were used in the rate comparisons. Values with
p <0.05 in two-tailed tests were considered statistically
signiﬁcant.
Results
Between 2001 and 2007, 643 cases of IPD were reported
in Navarre; in 555 cases (86%), an isolate was available for
serotyping and, in 551 cases (99%), a type was reported. The
crude average annual rate was 15.8, 15.3 and 16.3 cases per
100 000 inhabitants in the periods 2001–2002, 2003–2005
and 2006–2007, respectively.
Vaccination status of cases aged <5 years
The increasing coverage of PCV7 is reﬂected in the percent-
age of IPD cases <5 years of age who had received at least
one previous dose, which rose from 7% in the 2001–2002
period to 53% in 2006–2007, and in the percentage of those
with complete vaccination in accordance with their age at ﬁrst
vaccination, which rose from 0% to 33% (p <0.001) (Table 1).
All cases in the last period who had received at least one dose
of PCV7 were caused by non-PCV7 serotypes.
Among the IPD cases in children <5 years who had not
received any dose of PCV7, only 39% were caused by PCV7
serotypes. When comparing IPD cases in non-vaccinated and
completely vaccinated children, no differences were found
in the distribution by clinical form, proportion of cases requir-
ing hospitalization, or median length of hospital stay (Table 2).
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Incidence by age groups and serotypes
Between the ﬁrst and last period, the incidence rate did not
change signiﬁcantly either in children <5 years (percentage
change )12%; p 0.59) or in the overall population (+3%;
p 0.80). The IPD incidence from vaccine serotypes decreased
by 85% in children <5 years (p <0.001), the target age group
for the vaccine, by 68% in persons ‡65 years (p 0.004), and
by 45% in the population aged 5–64 years, although the lat-
ter reduction did not reach statistical signiﬁcance (p 0.10).
The incidence of IPD from non-vaccine serotypes increased
overall by 40% (p 0.006), with increases in all three age
groups, although they were not statistically signiﬁcant when
evaluated separately (Table 3).
Evolution in characteristics of cases
No signiﬁcant changes were seen in the incidence of any of
the clinical forms of IPD either in the joint analysis or in the
analysis stratiﬁed by age group (Table 4). Nor were there
important changes in the overall proportion of cases with
occult bacteraemia (13% and 15% in the ﬁrst and last period,
respectively; p 0.65).
Among cases aged <5 years, only one case presented risk
factors for IPD, and this case had received PCV7. In those
aged ‡5 years, risk factors for IPD were present in 54% of
cases in the 2001–2002 period and in 48% in 2006–2007 (p
0.47). The proportion of cases <5 years requiring hospitaliza-
tion was 68% in 2001–2002 and 64% in 2006–2007 (p 0.82)
and, in those ‡5 years, was 93% and 83%, respectively
(p 0.004). No deaths occurred in children <5 years, although
there were sequelae in 2% and 11% of cases in the ﬁrst and
last period, respectively (p 0.21). The proportion of deaths
as a result of IPD in cases ‡5 years was 15% and 17%, with
sequelae remaining in 7% and 7%, respectively (p 0.92)
(Table 5).
Evolution of serotype distribution
Table 6 shows the large diversity of serotypes isolated in the
IPD cases. In 2001–2002, PCV7 serotypes were isolated in
only 45% of IPD cases <5 years and 32% of those who were
older. In 2006–2007, the percentage of IPD cases caused by
PCV7-serotypes decreased, both in those <5years and in
those >5 years, mainly because of a reduction in the more
frequent serotypes, such as 14, 4 and 19F. On the other
hand, the percentage of non-PCV7 serotypes isolated
increased in both age groups, reaching statistical signiﬁcance
for serotypes 7 and 19A. The percentage of serotype 24 iso-
lates also increased signiﬁcantly when it was evaluated for all
ages (p 0.01).
The percentage of cases in which the serotype could not
be determined increased from 4% in the ﬁrst period to 24%
in the last period (p <0.001). These cases were less frequent
in children <5 years, and were not associated with the
clinical form or evolution of the disease or with vaccination
history.
Discussion
The introduction and increased coverage with PCV7 in
Navarre has been followed by important changes in the
pattern of serotypes causing IPD in both children and adults,
although the decline in IPD incidence has been much smaller
than would be expected from this change.
In children <5 years, the incidence of IPD caused by PCV7
serotypes has decreased by 85%, whereas the incidence
caused by non-PCV7 serotypes has increased by 47%, with
the result that the total incidence of IPD has declined by
only 12%. Fifty-three per cent of children <5 years diagnosed
TABLE 1. Vaccination history with heptavalent pneumo-
coccal conjugate vaccine in cases of invasive pneumococ-
cal disease diagnosed in children under 5 years in three
periods
PCV7 status
2001–2002 2003–2005 2006–2007
p-valuen (%) n (%) n (%)
Not vaccinated 38 (93) 50 (71) 21 (47) <0.001
Incomplete vaccination 3 (7) 9 (13) 9 (20)
Complete vaccination 0 (0) 11 (16) 15 (33)
Total 41 (100) 70 (100) 45 (100)
p-value for result of v2 test comparing 2001–2002 with 2006–2007.
TABLE 2. Type of pneumococcus and clinical form of cases
of invasive pneumococcal disease, by vaccination status
Not
vaccinated
Incomplete
vaccination
Complete
vaccination
p-valuen (%) n (%) n (%)
Type of pneumococcusa <0.001
Vaccine serotype 39 (39) 1 (5) 1 (4)
Non-vaccine serotype 62 (61) 18 (95) 24 (96)
Clinical form 0.26
Meningitis 6 (6) 1 (5) 3 (12)
Bacteraemic pneumonia 37 (34) 11 (52) 12 (46)
Other sites 20 (18) 2 (10) 5 (19)
Bacteraemia without focus 46 (42) 7 (33) 6 (23)
Hospitalized 78 (72) 12 (57) 18 (69) 0.81
Length of hospital stay,
median (interquartile range)
6 (4–11) 5 (3–14) 7 (4–15) 0.60
Total 109 (100) 21 (100) 26 (100)
p-value for result of v2, Fisher’s exact or Wilcoxon’s test comparing non-vacci-
nated cases with those receiving complete vaccination.
aDoes not include cases that were not typed.
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with IPD in 2006–2007 had received at least one dose of
PCV7, which is a similar percentage to that for the PCV7
coverage in the population in the same period and age
group. These data are consistent with studies in other
regions of Spain, which have shown a slight reduction in the
overall incidence of IPD and an important increase in the
incidence of IPD caused by non-vaccine serotypes after the
introduction of PCV7 [13,18].
PCV7 also has an important indirect effect on the non-
vaccinated population, which is attributable to herd immunity
[10,11]. This would explain the considerable decline in adults
of the incidence of IPD from PCV7 serotypes. In our study,
the indirect effect also appears to be accompanied by the
replacement of vaccine serotypes by others not included in
the vaccine, which is consistent with changes that have also
been detected in Portugal [19].
TABLE 3. Incidence of invasive pneumococcal disease in three periods, with percentage change and rate difference between
ﬁrst and last period, by serotype and age group
2001–2002 2003–2005 2006–2007 2006–2007 vs. 2001–2002
Cases
Cases /
100 000 Cases
Cases /
100 000 Cases
Cases /
100 000
Rate difference
Cases/100 000
% Change
in rate p-value
PCV7 serotypesa
<5 19 37.1 21 24.6 4 5.7 )31.4 )85 <0.001
5–64 19 2.2 29 2.1 11 1.2 )1.0 )45 0.10
‡65 24 11.8 34 11.1 8 3.7 )8.1 )68 0.004
All ages 62 5.5 84 4.8 23 1.9 )3.6 )66 <0.001
Non-PCV7 serotypesa
<5 22 45.3 49 57.7 41 66.7 +21.3 +47 0.21
5–64 52 6.0 61 4.5 70 7.5 +1.5 +26 0.24
‡65 42 20.6 74 23.7 63 30.0 +9.4 +46 0.06
All ages 116 10.3 184 10.5 174 14.4 +4.1 +40 0.006
All serotypes
<5 41 82.5 70 82.3 45 72.4 )10.0 )12 0.59
5–64 71 8.1 90 6.6 81 8.7 +0.5 +7 0.75
‡65 66 32.4 108 34.8 71 33.7 +1.3 +4 1
All ages 178 15.8 268 15.3 197 16.3 +0.5 +3 0.80
p-value of comparison of rates in the ﬁrst and the last periods.
aNon-typed cases were proportionally distributed between vaccine and non-vaccine categories.
TABLE 4. Incidence of invasive pneumococcal disease in three periods, with percentage change and rate difference between
ﬁrst and last period, by age group and clinical form of disease
Age group and clinical form
2001–2002 2003–2005 2006–2007 2006–2007 vs. 2001–2002
Cases /
100 000
Cases /
100 000
Cases /
100 000
Rate difference
Cases/100 000
% Change
in rate p-value
0–4 years
Meningitis 6.0 3.5 6.4 +0.4 +7 1
Bacteraemic pneumonia 38.2 25.9 30.6 )7.6 )20 0.52
Other sites 6.0 18.8 12.9 +6.8 +113 0.37
Bacteraemia without focus 32.2 34.1 22.5 )9.6 )30 0.36
Total 82.5 82.3 72.4 )10.0 )12 0.59
5–64 years
Meningitis 1.3 0.7 1.2 )0.1 )7 1
Bacteraemic pneumonia 6.0 4.8 6.2 +0.2 +4 0.85
Other sites 0.2 0.5 0.4 +0.2 +87 0.69
Bacteraemia without focus 0.7 0.6 0.7 +0.1 +9 1
Total 8.1 6.6 8.6 +0.4 +5 0.81
‡65 years
Meningitis 3.9 5.5 3.8 )0.1 )3 1
Bacteraemic pneumonia 26.5 24.8 24.7 )1.8 )7 0.77
Other sites 1.5 1.0 2.4 +0.9 +61 0.73
Bacteraemia without focus 0.5 3.5 2.8 +2.4 +480 0.13
Total 32.4 34.8 33.7 +1.3 +4 0.86
All ages
Meningitis 2.0 1.7 1.9 )0.1 )3 1
Bacteraemic pneumonia 11.1 9.4 10.7 )0.4 )4 0.80
Other sites 0.7 1.5 1.4 +0.7 +98 0.11
Bacteraemia without focus 2.0 2.7 2.2 +0.2 +9 0.68
Total 15.8 15.3 16.2 +0.4 +3 0.80
p-value of comparison of rates in the ﬁrst and the last periods.
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Considering the total population of Navarre, expansion of
PCV7 vaccination has been followed by a 66% reduction in
the incidence of IPD from vaccine serotypes, although the
incidence of IPD from all serotypes has not decreased.
Before the expansion of PCV7 coverage in Navarre, less than
half of IPD cases in both children and adults were caused by
serotypes included in the vaccine, as opposed to the situa-
tion in the USA, where this percentage exceeded 80% [1].
TABLE 5. Characteristics of cases
of invasive pneumococcal disease
by age group in two periods with
different coverage with the hepta-
valent pneumococcal conjugate
vaccine
Cases <5 years Cases ‡5 years
2001–2002 2006–2007
p value
2001–2002 2006–2007
p-valuen (%) n (%) n (%) n (%)
Sex 0.28 0.90
Male 18 (44) 26 (58) 90 (66) 101 (66)
Female 23 (56) 19 (42) 47 (34) 51 (34)
Any risk factor 0 (0) 1 (2) 1 72 (53) 68 (45) 0.20
Hospitalization 28 (68) 29 (64) 0.82 128 (93) 125 (83) 0.004
Evolutiona 0.21 0.92
Cured 40 (98) 40 (89) 101 (74) 116 (76)
Sequelae 1 (2) 5 (11) 9 (7) 10 (7)
Death from IPD 0 (0) 0 (0) 20 (15) 26 (17)
Death from other cause 0 (0) 0 (0) 7 (5) 0 (0)
Total 41 (100) 45 (100) 137 (100) 152 (100)
IPD, invasive pneumococcal disease.
aDeaths from other causes are excluded from the statistical comparison.
TABLE 6. Streptococcus pneumo-
niae serotypes identiﬁed in cases of
invasive pneumococcal disease in
two periods with different cover-
age with the heptavalent pneumo-
coccal conjugate vaccine (PCV7)
Cases aged <5 years Cases aged ‡5 years
2001–2002 2006–2007
p value
2001–2002 2006–2007
p-valuen (%) n (%) n (%) n (%)
PCV7 serotypes
4 0 (0) 0 (0) – 11 (8) 2 (2) 0.02
6B 3 (8) 0 (0) 0.24 1 (1) 1 (1) 1
9V 0 (0) 1 (3) 0.49 4 (3) 2 (2) 0.69
14 7 (18) 1 (3) 0.06 16 (12) 6 (5) 0.07
18C 2 (5) 0 (0) 0.49 1 (1) 1 (1) 1
19F 3 (8) 0 (0) 0.24 5 (4) 0 (0) 0.06
23F 3 (8) 1 (3) 0.62 3 (2) 2 (2) 1
Subtotal 18 (45) 3 (8) <0.001 41 (32) 14 (13) 0.001
Non PCV7 serotypes
1 5 (13) 5 (13) 1 19 (15) 15 (13) 0.85
3 4 (10) 2 (5) 0.68 19 (15) 14 (13) 0.71
5 0 (0) 1 (3) 0.49 0 (0) 0 (0) –
6A 6 (15) 2 (5) 0.26 7 (5) 3 (3) 0.35
7 1 (3) 7 (18) 0.03 8 (6) 17 (15) 0.03
8 0 (0) 0 (0) – 6 (5) 1 (1) 0.13
9N 0 (0) 0 (0) – 2 (2) 0 (0) 0.50
10 1 (3) 1 (3) 1 4 (3) 2 (2) 0.69
11 0 (0) 0 (0) – 4 (3) 3 (3) 1
12 0 (0) 1 (3) 0.49 1 (1) 2 (2) 0.60
15 1 (3) 1 (3) 1 2 (2) 0 (0) 0.50
16 0 (0) 0 (0) – 0 (0) 2 (2) 0.21
17 0 (0) 0 (0) – 1 (1) 1 (1) 1
18A 0 (0) 0 (0) – 0 (0) 1 (1) 0.46
19A 3 (8) 12 (32) 0.009 5 (5) 25 (22) <0.001
20 0 (0) 0 (0) – 0 (0) 1 (1) 0.46
22 0 (0) 0 (0) – 3 (3) 2 (2) 1
23A and B 1 (3) 0 (0) 1 1 (1) 2 (2) 0.60
24 0 (0) 2 (5) 0.23 0 (0) 4 (4) 0.04
28 0 (0) 0 (0) – 0 (0) 1 (1) 0.46
33 0 (0) 1 (3) 0.49 0 (0) 2 (2) 0.21
34 0 (0) 0 (0) – 2 (2) 0 (0) 0.50
35 0 (0) 0 (0) – 2 (2) 0 (0) 0.50
37 0 (0) 0 (0) – 1 (1) 0 (0) 1
Not subtyped 0 (0) 0 (0) – 2 (2) 0 (0) 0.50
Subtotal 22 (55) 35 (92) <0.001 89 (68) 98 (88) 0.001
Total subtyped 40 (100) 38 (100) 130 (100) 112 (100)
Not grown 1 0 0 2
Not subtyped 0 7 7 38
Total 41 45 137 152
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The decline in the incidence of IPD from PCV7 serotypes
has coincided with an increase in cases from non-PCV7 sero-
types, especially from serotypes 7 and 19A, a phenomenon
that can be interpreted as serotype replacement. This phe-
nomenon has been described in clinical trials [20,21], obser-
vational studies [22,23] and laboratory-based surveillance in a
variety of places subsequent to the introduction of PCV7
[18,19,23–30]. However, some similar changes in serotype
patterns have also been described in places where PCV7 had
not been introduced [31], indicating that some other secular
trend was playing a role.
An argument in favour of PCV7 is that it prevents the
most severe clinical forms of the disease. Although our
study does not have the statistical power to completely rule
out this hypothesis, we did not observe any signiﬁcant
decline in the proportion of cases with meningitis or
bacteraemic pneumonias. We detected a reduction in the
percentage of cases >5 years who required hospitalization,
but this trend had no effect on the clinical evolution of
the cases, which were distributed similarly in the two
periods.
When explaining the results of our study, some limitations
have to be considered. This was an ecological time-trend
study, which makes it difﬁcult to rule out the possibility that
factors other than the extension of PCV7 coverage may also
have contributed to the observed changes. Among the
factors that should be considered are the secular trend,
characteristics of the surveillance system, changes in culture
practices, antibiotic use and antibiotic resistant clones [31],
inﬂuenza epidemiology, and random variability.
Possible under-registration of IPD cases might also have
affected the results, but this was minimized by having an
active surveillance system that covers all six microbiology
laboratories in the region, and which is compared annually
with hospital discharge diagnoses. The change in the system
for requesting cultures could affect comparisons over time,
but this would be shown as changes in the percentage of
non-focal bacteraemias with respect to total IPD cases. This
percentage has increased only in persons ‡65 years, although
it fails to reach statistical signiﬁcance and, given its magni-
tude, would not cancel out the main results.
In 14% of cases, it was not possible to establish the sero-
type. In the analyses by serotype, these cases were excluded
or distributed proportionately among vaccine and non-vac-
cine serotypes according to those with known types for the
same period and age group [6,11]. This limitation would only
affect the results in the breakdown by serotypes. In the most
extreme case, the impact of the vaccine in reducing the inci-
dence of IPD from PCV7 serotypes and the increase in cases
from non-PCV7 serotypes would be attenuated.
The lack of statistical power could have prevented our
reaching conclusive results in some analyses, although the
ﬁndings that we have highlighted were sufﬁciently supported.
PCV7 coverage in Navarre is far from complete; however,
we found a sharp decrease in the incidence of IPD from PCV7
serotypes in children <5 years, of a magnitude similar to that
described in places with a higher coverage [5–8,11,24–28,32].
Moreover, 33% of the IPD cases in children <5 years had been
completely vaccinated and another 20% had received at least
one dose of vaccine, which could provide some protection
[32,33]. Taken together, this indicates that the main problem
is not the low coverage, but the low effectiveness of PCV7 in
Navarre in protecting against IPD in general, as demonstrated
in a case–control study [14].
Although we cannot rule out the role of other factors,
the results obtained in the present study are compatible with
the existence of an important direct and indirect effect of
PCV7 in the prevention of IPD from vaccine serotypes, and
also with an important replacement by non-vaccine serotypes
in both children and adults, which largely neutralizes the pre-
ventive impact of the vaccine. Until more conclusive studies
are available on the effectiveness of PCV7 and on the long-
term consequences of serotype replacement, serious doubts
will remain concerning the appropriateness of introducing it
into the routine vaccination schedule in Navarre. This may
also be applicable to other places where the serotypes
responsible for a substantial portion of invasive disease are
not included in the vaccine.
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